Dermata Therapeutics, Inc. (DRMA) Stock Price & Analysis
Dermata Therapeutics, Inc. (DRMA) fell 0.83% to USD 1.2 as of June 10, 2026 at 02:36 UTC, according to Nexqual real-time market data.
DRMA last closed at USD 1.21; the session ranged USD 1.2–1.28 on volume of 42,900 shares. Market capitalization is $4.83M, with a 52-week range of USD 1.1–8 (NCM). Source: Nexqual, June 10, 2026 at 02:36 UTC.
Key Statistics (as of June 10, 2026 at 02:36 UTC)
| Price | USD 1.2 |
|---|---|
| Change | ▼ 0.83% (down) |
| Previous Close | USD 1.21 |
| Open | USD 1.28 |
| Day Range | USD 1.2 – 1.28 |
| 52-Week Range | USD 1.1 – 8 |
| Volume | 42,900 shares |
| Market Cap | $4.83M |
| Exchange | NCM |
Technical Analysis (DRMA)
Nexqual's technical model rates DRMA "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:36 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.66 (neutral) |
| vs SMA50 | Below (USD 1.27) |
| MACD | -0.01 (negative) |
Analyst Ratings (DRMA)
Wall Street analysts rate DRMA "None" based on 1 analysts, with a mean price target of USD 4 (range USD 4–4), per Nexqual as of June 10, 2026 at 02:36 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 4 |
| High Target | USD 4 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (DRMA)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.48 vs est -0.53 ▲ beat |
| 2025-12-31 | USD -1.52 vs est -1.54 ▲ beat |
| 2025-09-30 | USD -1.65 vs est -1.59 ▼ miss |
| 2025-06-30 | USD -1.66 vs est -2.9 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financials & Fundamentals (DRMA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -103.58% |
| Current Ratio | 7.09 |
| Total Cash | $6.95M |
| Total Debt | $0 |
| Free Cash Flow | $-6.34M |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financial Health Score (DRMA)
Nexqual rates Dermata Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:36 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $7M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$8M |
| Efficiency | Critical — ROE -104%, ROA -52.7% |
Ownership (DRMA)
| Insider Ownership | +24.82% |
|---|---|
| Institutional Ownership | +7.37% |
| Shares Outstanding | 4.02M |
| Float | 3.17M |
| Short % of Float | +3.06% |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Leadership (DRMA)
Dermata Therapeutics, Inc. is led by Gerald T. Proehl (age 66), Founder, President, CEO & Chairman, per Nexqual as of June 10, 2026 at 02:36 UTC.
| Founder, President, CEO & Chairman | Gerald T. Proehl (age 66) |
|---|---|
| Co-Founder & Lead Independent Director | David F. Hale (age 76) |
| Senior VP & CFO | Kyri K. Van Hoose (age 47) |
| Vice President of Marketing | Kyra Peckaitis |
| Senior Vice President of Regulatory Affairs & Quality Assurance | Maria Bedoya Toro Munera (age 74) |
Major Backers & Investors (DRMA)
Notable institutional backers of Dermata Therapeutics, Inc. include Fidelity, UBS Group AG, Welch & Forbes, LLC, according to Nexqual as of June 10, 2026 at 02:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.2% |
| UBS Group AG | 0.89% |
| Welch & Forbes, LLC | 0.5% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.2% |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
From Dermata Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- The combination of a proprietary harvesting protocol, developed by our exclusive supplier, and the post-harvest processing procedures, produce an ingredient that we believe optimizes the mechanical components, which are silica microstructures also called spicules, as well as the organic components of Spongilla , while eliminating any harmful bacteria that could be found in many freshwater or marine sponges.
- With our proprietary harvesting protocols and manufacturing procedures, we are able to take Spongilla lacustric raw material and leverage the combination of evolution and scientific innovation to create a unique product we like to call, Bioneedle.
- Our product development strategy is centered on the scalable use of our proprietary Bioneedle as the foundation for any well-rounded skincare routine.
- BDS works by first topically applying our proprietary sponge powder to the treatment area wherein the mechanical Bioneedles penetrate the skin, thereby creating millions of microchannels into the dermis similar to the Image 4 below.
Partnerships
- One such location is the Volga River, where we have signed an exclusive supply agreement with one of the larger known suppliers of wild harvested Spongilla raw material for our Tome skincare line, which we believe provides us with a reliable source of our supply of Spongilla raw material for the foreseeable future.
- In February 2020, we signed an exclusive supply agreement with this supplier of Spongilla raw material .
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBLG | Bone Biologics Corp | USD 1.23 | ▼ 1.52% |
| REVB | Revelation Biosciences, Inc. | USD 1.04 | ▲ 5.05% |
| RNAZ | TransCode Therapeutics, Inc. | USD 4.98 | ▼ 11.07% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| PALI | Palisade Bio, Inc. | USD 1.69 | ▼ 2.87% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:36 UTC. This page is informational and not investment advice.